Ghost Tree Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Ghost Tree Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$6.47M	Sell	128,411 -171,589	-57%	-$8.04M	1.96%	21
2024 Q2	$13.2M	Hold	300,000	–	–	4.13%	4
2024 Q1	$15.1M	Buy	300,000 +220,000	+275%	+$11.9M	4.17%	5
2023 Q4	$4.83M	Sell	80,000 -250,000	-76%	-$12.9M	1.58%	19
2023 Q3	$18.8M	Hold	330,000	–	–	6.19%	2
2023 Q2	$16.8M	Buy	330,000 +135,000	+69%	+$3.63M	5.56%	3
2023 Q1	$4.17M	Buy	+195,000	New	+$3.28M	1.23%	31
2022 Q4	–	Sell	-300,000	Closed	-$2.33M	–	41
2022 Q3	$2.33M	Hold	300,000	–	–	0.65%	35
2022 Q2	$1.57M	Buy	+300,000	New	+$1.89M	0.82%	29
2021 Q4	–	Sell	-500,000	Closed	-$4.94M	–	64
2021 Q3	$4.94M	Hold	500,000	–	–	1.45%	26
2021 Q2	$5.17M	Hold	500,000	–	–	1.42%	26
2021 Q1	$5.12M	Hold	500,000	–	–	1.2%	27
2020 Q4	$5.68M	Buy	+500,000	New	+$5.31M	1.27%	26

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ghost Tree Capital's MLTX Position: Q3 2024 in Review

Ghost Tree Capital reduced its MoonLake Immunotherapeutics (MLTX) stake by 57% in Q3 2024, selling an estimated $8.04M and leaving 128,411 shares worth $6.47M. The position accounts for 1.96% of the portfolio, ranked #21.

Ghost Tree Capital first reported a position in MLTX in Q4 2020 and has held it in 13 quarters since. The position peaked at $18.8M in Q3 2023. 109 funds tracked by Wall St. Rank hold MLTX as of Q3 2024.

Ghost Tree Capital held 128,411 shares of MoonLake Immunotherapeutics worth $6.47M as of Q3 2024.
Ghost Tree Capital sold 171,589 MoonLake Immunotherapeutics shares in Q3 2024, an estimated $8.04M.
MoonLake Immunotherapeutics made up 1.96% of Ghost Tree Capital's portfolio in Q3 2024, its #21 holding.
Ghost Tree Capital first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 13 quarters since.
Ghost Tree Capital's MoonLake Immunotherapeutics position peaked at $18.8M in Q3 2023.
109 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.